Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Joe Camel "supplements" his portfolio

This article was originally published in The Tan Sheet

Executive Summary

RJ Reynolds Tobacco Company's Avoca division and Next Pharmaceuticals have partnered to develop proprietary dietary supplement ingredients, the firms announce March 8. Flagship Nextracts include the COX-2 anti-inflammatory Nexprofen and Relora, a phenolic complex for anxiety and stress. Others are Standardized Echinacea Purpurea Nextract with 4% phenolic compounds and four Standardized Saw Palmetto Nextracts containing 10%, 25%, 30% and 40% total fatty acids, respectively. The January agreement follows 18 months of R&D; the agricultural and extraction facilities are located at Avoca's 2,400-acre North Carolina facility. Next is courting large pharmaceutical and supplement companies as part of the ingredients' "roll-out" phase
Advertisement

Related Content

Relora supplement launch
Relora supplement launch
Relora supplement launch
Natrol Fiber, Cleansing Teas Headline New Product Launches
Natrol Fiber, Cleansing Teas Headline New Product Launches
Natrol Fiber, Cleansing Teas Headline New Product Launches

Topics

Advertisement
UsernamePublicRestriction

Register

PS090995

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel